Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series
(2020) In Contact Dermatitis 83(4). p.301-309- Abstract
Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a... (More)
Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a questionnaire. Results: Thirteen patients were sensitized to IBOA and four to DMAA. Two positive reactions to IBOA and one to DMAA were seen only at 0.3% concentration on D7. Median duration of sensor use before dermatitis onset was 6 months. Half the number of the patients took precautions in everyday life due to sensor-related skin reactions. Six patients discontinued sensor usage. Conclusions: Patients with suspected ACD to glucose sensors should be evaluated with a relevant patch test series containing IBOA and DMAA. Adding the 0.3% pet. concentration is recommended. The reading on D7 is necessary.
(Less)
- author
- Ulriksdotter, Josefin LU ; Svedman, Cecilia LU ; Bruze, Magnus LU ; Glimsjö, Jenny ; Källberg, Kajsa ; Sukakul, Thanisorn LU and Mowitz, Martin LU
- organization
- publishing date
- 2020-10-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- adhesive, allergic contact dermatitis, diabetes mellitus, FreeStyle Libre, glucose sensor, isobornyl acrylate, medical device, N,N-dimethylacrylamide
- in
- Contact Dermatitis
- volume
- 83
- issue
- 4
- pages
- 9 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:32608015
- scopus:85088638175
- ISSN
- 0105-1873
- DOI
- 10.1111/cod.13649
- language
- English
- LU publication?
- yes
- id
- 6d3a8fb5-09a5-4da9-af88-14f9d719422a
- date added to LUP
- 2020-09-30 15:40:50
- date last changed
- 2024-09-06 04:13:10
@article{6d3a8fb5-09a5-4da9-af88-14f9d719422a, abstract = {{<p>Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a questionnaire. Results: Thirteen patients were sensitized to IBOA and four to DMAA. Two positive reactions to IBOA and one to DMAA were seen only at 0.3% concentration on D7. Median duration of sensor use before dermatitis onset was 6 months. Half the number of the patients took precautions in everyday life due to sensor-related skin reactions. Six patients discontinued sensor usage. Conclusions: Patients with suspected ACD to glucose sensors should be evaluated with a relevant patch test series containing IBOA and DMAA. Adding the 0.3% pet. concentration is recommended. The reading on D7 is necessary.</p>}}, author = {{Ulriksdotter, Josefin and Svedman, Cecilia and Bruze, Magnus and Glimsjö, Jenny and Källberg, Kajsa and Sukakul, Thanisorn and Mowitz, Martin}}, issn = {{0105-1873}}, keywords = {{adhesive; allergic contact dermatitis; diabetes mellitus; FreeStyle Libre; glucose sensor; isobornyl acrylate; medical device; N,N-dimethylacrylamide}}, language = {{eng}}, month = {{10}}, number = {{4}}, pages = {{301--309}}, publisher = {{Wiley-Blackwell}}, series = {{Contact Dermatitis}}, title = {{Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series}}, url = {{http://dx.doi.org/10.1111/cod.13649}}, doi = {{10.1111/cod.13649}}, volume = {{83}}, year = {{2020}}, }